NAS:NBSE (USA) Also Trade In: Germany
NeuBase Therapeutics Inc $ 7.6 -0.2 (-2.56%)
Warning! GuruFocus has detected 2 Severe warning signs with NBSE. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for NeuBase Therapeutics Inc () from 2004 to Sep 28 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. NeuBase Therapeutics stock (NBSE) PE ratio as of Sep 28 2020 is 0. More Details
NeuBase Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2004. Start your Free Trial
NeuBase Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:BCLI NAS:APTX NAS:JNCE NAS:NCNA NAS:AYLA NAS:AQST NAS:OBSV NAS:TYME AMEX:OCX NAS:SLGL OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 700 Technology Drive, Pittsburgh, PA, USA, 15219
NeuBase Therapeutics Inc is pre-clinical stage bio-pharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.